GENFIT (NASDAQ:GNFT) Now Covered by Analysts at HC Wainwright

Key Points

Error: Response status code does not indicate success: 429 (Too Many Requests).

Equities researchers at HC Wainwright initiated coverage on shares of GENFIT (NASDAQ:GNFT - Get Free Report) in a research report issued to clients and investors on Tuesday, MarketBeat reports. The firm set a "buy" rating and a $9.00 price target on the stock. HC Wainwright's price target indicates a potential upside of 108.53% from the stock's previous close. HC Wainwright also issued estimates for GENFIT's FY2025 earnings at $0.01 EPS, FY2026 earnings at ($0.90) EPS, FY2027 earnings at ($0.24) EPS, FY2028 earnings at ($0.90) EPS and FY2029 earnings at ($0.64) EPS.

GENFIT Price Performance

Shares of GENFIT stock traded up $0.1960 during trading on Tuesday, hitting $4.3160. The company's stock had a trading volume of 1,582 shares, compared to its average volume of 3,812. The company has a quick ratio of 1.23, a current ratio of 1.23 and a debt-to-equity ratio of 0.08. The company has a fifty day simple moving average of $3.90 and a two-hundred day simple moving average of $3.86. GENFIT has a 52 week low of $2.55 and a 52 week high of $6.42.

Hedge Funds Weigh In On GENFIT

An institutional investor recently bought a new position in GENFIT stock. OLD Mission Capital LLC purchased a new stake in GENFIT S.A. Unsponsored ADR (NASDAQ:GNFT - Free Report) during the first quarter, according to the company in its most recent Form 13F filing with the SEC. The firm purchased 22,238 shares of the company's stock, valued at approximately $76,000. 2.24% of the stock is owned by hedge funds and other institutional investors.

GENFIT Company Profile

Genfit SA, a late-stage biopharmaceutical company, discovers and develops drug candidates and diagnostic solutions for metabolic and liver-related diseases. The company develops Elafibranor, which is in Phase III clinical trial to treat patients with primary biliary cholangitis. It also engages in the development of NIS4 technology for the diagnosis of nonalcoholic steatohepatitis (NASH) and fibrosis; VS-01 for the treatment of Urea Cycle Disorder (UCD) and Organic Acidemia Disorder (OAD); GNS561, which is in Phase 1b/2a trial to treat patients with cholangiocarcinoma (CCA); VS-01-ACLF and Nitazoxanide (NTZ), which is in Phase 1 trial to treat acute-on-chronic liver failure, as well as VS-02-HE, which is in preclinical trial for the treatment of Reduction of Hyperammonemia and the Stabilization of Blood Ammonia; CML-022; SRT-015, an ASK1 inhibitor targets the inhibition of cellular apoptosis, inflammation, and fibrosis.